Xeris Biopharma SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

10-QNov. 5, 2026, 4:08 p.m. ETView on SEC.gov
8-KNov. 5, 2026, 7:12 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedXeris Biopharma Q3 2026 diluted EPS $0.06 beats $0.027 consensus; revenue $107.2 million tops $101.7 million; full-year revenue guidance raised to $395-$405 million
4Nov. 4, 2026, 4:58 p.m. ETView on SEC.gov
4Nov. 4, 2026, 4:57 p.m. ETView on SEC.gov
4Nov. 4, 2026, 4:57 p.m. ETView on SEC.gov
4Nov. 4, 2026, 4:56 p.m. ETView on SEC.gov
8-KNov. 2, 2026, 8:05 a.m. ETView on SEC.gov
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedXeris Biopharma Appoints Menassie Taddese to Board of Directors and Audit Committee
SCHEDULE 13G/AOct. 30, 2026, 12:35 p.m. ETView on SEC.gov
8-KOct. 14, 2026, 7:08 a.m. ETView on SEC.gov
Other events
AI summary, unreviewedXeris Biopharma Files Patent Infringement Suits Against Generic Keveyis (dichlorphenamide) Makers Following '502 Patent Grant
4Oct. 2, 2026, 4:54 p.m. ETView on SEC.gov
4Oct. 2, 2026, 4:54 p.m. ETView on SEC.gov
4Oct. 2, 2026, 4:54 p.m. ETView on SEC.gov
4Sept. 29, 2026, 4:59 p.m. ETView on SEC.gov
8-KSept. 9, 2026, 8:33 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
4Sept. 1, 2026, 6:21 p.m. ETView on SEC.gov
4Sept. 1, 2026, 6:20 p.m. ETView on SEC.gov
4Sept. 1, 2026, 6:21 p.m. ETView on SEC.gov
4Aug. 21, 2026, 4:23 p.m. ETView on SEC.gov
4Aug. 21, 2026, 4:15 p.m. ETView on SEC.gov
4Aug. 12, 2026, 4:44 p.m. ETView on SEC.gov
10-QAug. 6, 2026, 4:07 p.m. ETView on SEC.gov
8-KAug. 6, 2026, 7:12 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
4Aug. 4, 2026, 5:30 p.m. ETView on SEC.gov
4Aug. 4, 2026, 5:16 p.m. ETView on SEC.gov
SCHEDULE 13GJuly 31, 2026, 10:41 a.m. ETView on SEC.gov